We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Read MoreHide Full Article
Key Takeaways
Abbott's i-STAT TBI test is now approved in Canada for rapid concussion detection using whole blood.
ABT's test uses brain biomarkers to deliver lab-quality results in 15 minutes via a portable device.
Abbott's approval expands its TBI offerings and supports quicker care within 24 hours of injury.
Abbott Laboratories (ABT - Free Report) recently received Health Canada approval for the i-STAT TBI test cartridge for use with whole blood. It is designed to help clinicians assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
The latest approval expands the company’s TBI test offerings, which include the i-STAT TBI Plasma test, and the ARCHITECT and Alinity i lab test (serum and plasma).
ABT Stock’s Likely Trend Following the News
Following the announcement, Abbott’s shares edged down 1.2%, finishing at $134.01 on Monday.
On a positive note, Abbott’s accelerated investments in the R&D pipeline are yielding positive results. Hence, we expect the market sentiment toward ABT stock to turn positive surrounding the latest approval.
Abbott holds a market capitalization of $230.37 billion. The company’s earnings yield of 3.9% surpasses the industry’s 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters.
About Abbott’s i-STAT TBI Test Cartridge Usage
For decades, standard TBI assessment has remained the same, with doctors leveraging tools, such as the Canadian CT Head Rule, which uses the Glasgow Coma Scale to detect brain tissue damage or lesions. However, the whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older with suspected mild traumatic brain injury (mTBI), commonly known as a concussion. The blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. The i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury.
The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), which are released into the blood stream during a significant brain injury. Testing for these two biomarkers following an injury can provide essential and objective information about a patient's condition and help healthcare providers choose an appropriate treatment plan.
Image Source: Zacks Investment Research
Industry Prospect Favors ABT
Per a report by Brain Injury Canada, an estimated 165 million Canadians will experience a TBI in 2025. Likewise, the Government of Canada released a report stating that each year more than 20 million people are hospitalized for TBI in the country, and the injury can range from mild to severe and include concussions. Even a mild form of TBI can have long-term consequences. Among all types of TBIs, concussions are the most common, accounting for approximately 80-95% of such injuries.
Another Development by Abbott
Last month, Abbott received Food and Drug Administration (“FDA”) approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC).
ABT Stock Price Performance
Over the past year, Abbott’s shares have risen 27.3%, surpassing the industry’s 8.4% growth.
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8%. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Key Takeaways
Abbott Laboratories (ABT - Free Report) recently received Health Canada approval for the i-STAT TBI test cartridge for use with whole blood. It is designed to help clinicians assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
The latest approval expands the company’s TBI test offerings, which include the i-STAT TBI Plasma test, and the ARCHITECT and Alinity i lab test (serum and plasma).
ABT Stock’s Likely Trend Following the News
Following the announcement, Abbott’s shares edged down 1.2%, finishing at $134.01 on Monday.
On a positive note, Abbott’s accelerated investments in the R&D pipeline are yielding positive results. Hence, we expect the market sentiment toward ABT stock to turn positive surrounding the latest approval.
Abbott holds a market capitalization of $230.37 billion. The company’s earnings yield of 3.9% surpasses the industry’s 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters.
About Abbott’s i-STAT TBI Test Cartridge Usage
For decades, standard TBI assessment has remained the same, with doctors leveraging tools, such as the Canadian CT Head Rule, which uses the Glasgow Coma Scale to detect brain tissue damage or lesions. However, the whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older with suspected mild traumatic brain injury (mTBI), commonly known as a concussion. The blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. The i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury.
The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), which are released into the blood stream during a significant brain injury. Testing for these two biomarkers following an injury can provide essential and objective information about a patient's condition and help healthcare providers choose an appropriate treatment plan.
Image Source: Zacks Investment Research
Industry Prospect Favors ABT
Per a report by Brain Injury Canada, an estimated 165 million Canadians will experience a TBI in 2025. Likewise, the Government of Canada released a report stating that each year more than 20 million people are hospitalized for TBI in the country, and the injury can range from mild to severe and include concussions. Even a mild form of TBI can have long-term consequences. Among all types of TBIs, concussions are the most common, accounting for approximately 80-95% of such injuries.
Another Development by Abbott
Last month, Abbott received Food and Drug Administration (“FDA”) approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC).
ABT Stock Price Performance
Over the past year, Abbott’s shares have risen 27.3%, surpassing the industry’s 8.4% growth.
ABT’s Zacks Rank and Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , Hims & Hers Health (HIMS - Free Report) and Cencora (COR - Free Report) .
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
ALGN sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8%. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.